Key facts
- Bionic Sight’s last known valuation is $59.0M (Mar 2020).
- It has raised $10.2M; the latest was Later Stage VC in Feb 2025.
- Notable investors include Raptor Group, Samsara BioCapital, Applied Genetic Technologies, Cornell University, Partnership Fund for New York City.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Bionic Sight
- ·The full record, as it builds
Funding rounds
No funding rounds for Bionic Sight are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bionic Sight
Developer of a medical device designed to develop and commercialize prosthetic treatments for blindness due to retinal degenerative disease. The company's device uses code that can convert visual images into similar patterns of an action potential that the retina normally produces and can do so across a broad range of stimuli including faces, landscapes, and movement, essentially replicating patterns in a code the brain is expecting and can recognize, enabling users to bring prosthetic capabilities up to the level of near-normal image representation.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2012
- Employees
- 5
- Website
- bionicsightllc.com/
- Ownership
- Privately Held (backing)
Bionic Sight doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bionic Sight shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bionic Sight in its N-PORT filings yet. We sweep new filings monthly.